The Oncotype DX® trial was validated with level 1A evidence for prognosis and predicts the benefit of adjuvant chemotherapy in node-negative, ER-positive, HER2-negative early breast cancer (post- or pre-menopausal) and in node-positive post-menopausal cases. Here, ERBB2 is linked to breast carcinoma.